Exxonmobil Investment Management Inc. TX Sells 7,383 Shares of Hologic, Inc. (HOLX)

Exxonmobil Investment Management Inc. TX trimmed its stake in Hologic, Inc. (NASDAQ:HOLX) by 14.4% in the fourth quarter, HoldingsChannel.com reports. The firm owned 43,835 shares of the medical equipment provider’s stock after selling 7,383 shares during the period. Exxonmobil Investment Management Inc. TX’s holdings in Hologic were worth $1,874,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Vanguard Group Inc. increased its holdings in Hologic by 4.2% in the second quarter. Vanguard Group Inc. now owns 29,547,138 shares of the medical equipment provider’s stock valued at $1,340,850,000 after purchasing an additional 1,200,825 shares during the period. Parnassus Investments CA acquired a new stake in Hologic in the third quarter valued at $277,062,000. Capital World Investors acquired a new stake in Hologic in the second quarter valued at $312,441,000. Victory Capital Management Inc. increased its holdings in Hologic by 16.8% in the third quarter. Victory Capital Management Inc. now owns 5,856,778 shares of the medical equipment provider’s stock valued at $214,885,000 after purchasing an additional 844,426 shares during the period. Finally, Northern Trust Corp increased its holdings in Hologic by 2.5% in the second quarter. Northern Trust Corp now owns 3,277,739 shares of the medical equipment provider’s stock valued at $148,743,000 after purchasing an additional 79,697 shares during the period. Institutional investors and hedge funds own 97.58% of the company’s stock.

Shares of Hologic, Inc. (HOLX) opened at $43.75 on Wednesday. The company has a current ratio of 0.79, a quick ratio of 0.61 and a debt-to-equity ratio of 0.79. Hologic, Inc. has a 1-year low of $35.76 and a 1-year high of $46.80. The firm has a market capitalization of $12,050.13, a PE ratio of 16.57, a price-to-earnings-growth ratio of 2.09 and a beta of 0.95.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.49 by $0.01. Hologic had a return on equity of 21.69% and a net margin of 24.70%. The firm had revenue of $802.90 million during the quarter, compared to the consensus estimate of $792.54 million. During the same period last year, the business posted $0.52 EPS. The business’s revenue was up 10.5% compared to the same quarter last year. sell-side analysts predict that Hologic, Inc. will post 2.15 earnings per share for the current year.

A number of research firms recently weighed in on HOLX. BidaskClub downgraded Hologic from a “hold” rating to a “sell” rating in a report on Saturday. Needham & Company LLC restated a “buy” rating and issued a $50.00 price objective (up from $48.00) on shares of Hologic in a report on Tuesday, January 9th. Bank of America upgraded Hologic from a “neutral” rating to a “buy” rating and set a $50.00 price objective for the company in a report on Thursday, January 4th. Evercore ISI started coverage on Hologic in a report on Wednesday, January 3rd. They set an “outperform” rating and a $50.00 price target for the company. Finally, Cowen upgraded Hologic to a “buy” rating and set a $52.00 price target for the company in a report on Wednesday, December 20th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $48.79.

In other news, VP Karleen Marie Oberton sold 1,023 shares of the firm’s stock in a transaction dated Monday, November 20th. The stock was sold at an average price of $39.84, for a total value of $40,756.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Elaine Ullian sold 9,282 shares of the firm’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $40.50, for a total value of $375,921.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 12,099 shares of company stock valued at $487,223. Company insiders own 0.79% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Exxonmobil Investment Management Inc. TX Sells 7,383 Shares of Hologic, Inc. (HOLX)” was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://sportsperspectives.com/2018/01/17/exxonmobil-investment-management-inc-tx-sells-7383-shares-of-hologic-inc-holx.html.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply